Target intelligence / Profile preview

Streptococcus pneumoniae DNA gyrase (DNA gyrase) (DNA gyrase)

Target
DNA gyrase
Molecular classification
Enzyme, Type II topoisomerase, Isomerase
01

Overview

Streptococcus pneumoniae DNA gyrase is an essential bacterial enzyme belonging to the type II topoisomerase family, composed of two GyrA and two GyrB subunits (UniProt P0C0V1, P0A4L9). It plays a critical role in maintaining DNA topology by introducing negative supercoils into the bacterial chromosome, which is vital for DNA replication, transcription, and recombination (ASM, 1.2.1). By relieving torsional stress ahead of the replication fork, the enzyme ensures the smooth progression of the replication machinery (NIH, 1.3.1). In the context of disease, Streptococcus pneumoniae is a major human pathogen responsible for pneumonia, meningitis, and sepsis, making its DNA gyrase a primary target for antimicrobial therapy (NIH, 1.4.4). Drugs such as fluoroquinolones bind to the gyrase-DNA complex, trapping it in a covalent intermediate state that leads to lethal double-strand DNA breaks (MDPI, 1.3.4). While fluoroquinolones also target topoisomerase IV in S. pneumoniae, DNA gyrase remains a critical secondary or primary target depending on the specific drug structure (ASM, 1.3.1). However, the clinical utility of these drugs is increasingly challenged by the emergence of resistance mutations within the quinolone resistance-determining regions (QRDRs) of the GyrA and GyrB subunits (NIH, 1.4.3).

Other names
Topoisomerase IIGyrA/GyrB complexDNA topoisomerase (ATP-hydrolyzing)GyrA/GyrB tetramer
02

Mechanism of action

Inhibition of DNA gyrase by stabilizing the enzyme-DNA covalent cleavage complex, which prevents DNA re-ligation and results in lethal double-strand DNA breaks.

03

Biological functions

DNA replicationDNA supercoilingTranscriptionDNA repairDNA recombination
04

Disease associations

InfectionPneumoniaMeningitisBacteremiaOtitis media
05

Safety considerations

Development of antimicrobial resistanceTendon ruptureQT interval prolongationCentral nervous system toxicityDysglycemia
06

Interacting drugs

Levofloxacin

8 more in the full profile.

07

Biomarkers

GyrA mutations (e.g., Ser-83)GyrB mutations (e.g., Glu-474)Minimum Inhibitory Concentration (MIC)Quinolone resistance-determining region (QRDR) mutations

Beyond the preview

Go deeper on Streptococcus pneumoniae DNA gyrase (DNA gyrase) (DNA gyrase).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Streptococcus pneumoniae DNA gyrase (DNA gyrase) (DNA gyrase).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call